CERE-110 gene therapy begins Phase II trial
Sunday 01 April 2012
Ceregene, an American biotech company, has begun a Phase II clinical study of CERE-110. This gene therapy product is designed to deliver nerve growth factor (NGF) to the brain for the treatment of Alzheimer's disease.
NGF is known to promote survival of cholinergic neurons. These neurons produce acetylcholine and degenerate during the course of Alzheimer's disease. The clinical trial involves direct delivery of CERE-110 into the brain, specifically to an area called the Nucleus Basalis of Meynert that is rich in acetylcholine. The trial will be conducted with 50 patients at 11 US research sites.